Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The company’s AN9025 will shortly enter phase 1.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
A more comprehensive dataset on JANX007 sends the group’s stock down.
But the group still hopes to get IGV-001 approved based on overall survival data.
